Financials CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
3.26 USD 0.00% Intraday chart for CureVac N.V. -11.17% -22.57%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 11,713 5,645 1,072 854.1 684.4 - -
Enterprise Value (EV) 1 10,443 4,862 605 854.1 598 500.2 572
P/E ratio -67.7 x -13.7 x -4.27 x -3.23 x -3.18 x -5.69 x -9.08 x
Yield - - - - - - -
Capitalization / Revenue 240 x 54.8 x 15.9 x 15.9 x 12.1 x 7.92 x 5.57 x
EV / Revenue 214 x 47.2 x 8.97 x 15.9 x 10.6 x 5.79 x 4.66 x
EV / EBITDA -105 x -6.38 x -2.68 x -3.41 x -3.47 x -3.11 x -4.92 x
EV / FCF 21.5 x -5.67 x -1.62 x - -1.75 x -2.79 x -7.84 x
FCF Yield 4.65% -17.6% -61.8% - -57.2% -35.8% -12.8%
Price to Book 12.3 x 8.2 x 2.06 x - 4.28 x 8.42 x -5.39 x
Nbr of stocks (in thousands) 176,460 187,050 190,244 223,924 224,292 - -
Reference price 2 66.38 30.18 5.634 3.814 3.051 3.051 3.051
Announcement Date 4/15/21 4/28/22 4/25/23 4/24/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 17.42 48.9 103 67.42 53.8 56.61 86.44 122.8
EBITDA 1 - -99.14 -762.4 -225.7 -250.8 -172.5 -160.7 -116.2
EBIT 1 - -109.8 -778.1 -249.5 -274.2 -226.9 -156 -92.93
Operating Margin - -224.54% -755.53% -370% -509.67% -400.86% -180.5% -75.68%
Earnings before Tax (EBT) 1 - -129.8 -412.5 -249.2 -260 -228.4 -160.2 -112.4
Net income 1 - -129.1 -411.7 -249 -260.2 -211.1 -129.5 -65.23
Net margin - -264.05% -399.76% -369.37% -483.58% -372.94% -149.86% -53.12%
EPS 2 -137.4 -0.9800 -2.210 -1.320 -1.180 -0.9603 -0.5364 -0.3362
Free Cash Flow 1 - 486.1 -857.4 -374.2 - -342 -179 -73
FCF margin - 994.02% -832.46% -555.03% - -604.12% -207.08% -59.45%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 4/29/20 4/15/21 4/28/22 4/25/23 4/24/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 29.36 41.22 24.4 20.1 11.2 11.69 7.129 7.579 16.5 22.6 12.37 12.15 14.2 13.53 3.545
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -143.1 -371.4 -15.27 -60.3 -52.4 -121.5 -60.36 -71.8 -54.04 -88 -73.32 -58.3 -52.26 -52.81 -64.8
Operating Margin -487.15% -900.84% -62.57% -300% -467.86% -1,039.52% -846.61% -947.37% -327.49% -389.38% -592.56% -479.75% -368.07% -390.27% -1,827.93%
Earnings before Tax (EBT) 1 - -4.559 -15.2 -57.6 - -128.8 -57.42 -67.39 -48.7 -86.5 -69.89 -74.07 -65.25 -61.99 -
Net income 1 - -1.936 -15.09 -57.58 - -128.8 -57.42 -67.41 -48.68 -86.65 -70.55 -55.66 -50.38 -46.5 -
Net margin - -4.7% -61.86% -286.49% - -1,101.75% -805.43% -889.48% -295.04% -383.42% -570.22% -458.02% -354.86% -343.62% -
EPS 2 - - -0.0800 -0.3100 -0.2500 -0.6800 -0.2700 -0.3000 -0.2200 -0.3900 -0.3100 -0.2482 -0.2318 -0.2195 -0.2737
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 12/17/21 4/28/22 5/25/22 8/18/22 11/16/22 4/25/23 5/30/23 8/17/23 11/14/23 4/24/24 5/23/24 - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 1,270 783 467 - 86.4 184 112
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - 486 -857 -374 - -342 -179 -73
ROE (net income / shareholders' equity) - -38.6% -58.8% -40.8% - -65.6% -101% -85.3%
ROA (Net income/ Total Assets) - - -30.8% -24.7% - -14.1% -20% 0.11%
Assets 1 - - 1,335 1,009 - 1,498 648.8 -59,484
Book Value Per Share 2 - 5.380 3.680 2.740 - 0.7100 0.3600 -0.5700
Cash Flow per Share 2 - 3.950 -3.940 -1.510 - -0.5600 -0.4000 -0.4900
Capex 1 - 36.3 124 88 - 65.1 85.2 85.3
Capex / Sales - 74.29% 120.62% 130.56% - 115.06% 98.52% 69.49%
Announcement Date 4/29/20 4/15/21 4/28/22 4/25/23 4/24/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.051 EUR
Average target price
8.733 EUR
Spread / Average Target
+186.20%
Consensus
  1. Stock Market
  2. Equities
  3. CVAC Stock
  4. Financials CureVac N.V.